{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.2","upperLimit":"77.5","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The length of time during and after the treatment that patients live with the disease, but it does not get worse. Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.\n\nResponding patients, according to the Lugano classification response Criteria, and patients who are lost to follow-up will be censored at their last assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with relapsed/refractory CD38 positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of TFH cell origin.","id":"OG000","title":"One Arm"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"The endpoint will be assessed from the start date of therapy up to 3 months.","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Percent probability at 3 months"}